Cabonzantinib, a cancer drug that potentially could target multiple forms of the deadly disease as well as tumor-related bone pain, was submitted last month for Food and Drug Administration approval for a form of thyroid cancer. The treatment, known as “cabo” for short, takes South San Francisco-based Exelixis the closest to selling a drug after 18 years and a cumulative deficit of $1.1 billion.
No comments:
Post a Comment